IceCure Medical Ltd
ICCMHealthcareNASDAQMedical Devices · Last scanned Jul 22, 2026
Scan Results
Daily timeframePart of the healthcare sector, IceCure Medical Ltd (ICCM) is listed under Medical Devices. Valued at $11.5M, ICCM is a micro-cap name in its sector. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.
Market Cap
$11.5M
Beta
1.54
P/E (TTM)
—
P/E (Fwd)
-1.34
EPS (TTM)
$-7.26
EPS (Fwd)
$-2.51
ROE
-217.2%
ROA
-80.3%
Cash
$8.1M
Total Debt
$139,000
Free CF
-$8.9M
52W Change
-88.6%
Annual Financials
Cash vs Debt
Where ICCM stands vs its 150-day and 200-day moving averages
As of the July 13, 2026 close, ICCM finished 72.54% below its 150-day moving average ($13.29) and 77.30% below its 200-day moving average ($16.08). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is ICCM overbought or oversold?
At the July 13, 2026 close, ICCM's RSI(14) was 41.7, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
IceCure Medical Ltd holds $8.1M in cash against $139K in total debt, giving it a net cash position. This means the company could theoretically pay off all its debt and still have cash remaining. The company is burning cash, with free cash flow at -$8.9M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -217.2%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has been relatively flat, moving from $3.1M (2022) to $3.4M (2025).
IceCure Medical Ltd's elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. With cash comfortably exceeding debt, ICCM has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence IceCure Medical Ltd's trajectory.